Anthera Pharma Loss Widens On Higher Research Costs

(RTTNews) - Anthera Pharmaceuticals Inc (ANTH) said Friday its net loss for the third quarter widened to $7 million or $0.31 per share from $5.8 million or $0.30 per share last year.

Analysts polled by Thomson Reuters estimated a loss of $0.39 per share for the quarter. Analysts' estimates typically exclude special items.

The company said results were hurt mainly by increased research expenses as a result of continued enrollment progress in both its Phase 3 systemic lupus erythematosus clinical study, CHABLIS-SC1, and Phase 2/3 IgA nephropathy clinical study, BRIGHT-SC.